Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about P2Y12: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
P2Y12 is a protein involved in neurodegeneration research. Key relationships include: activates, targets, associated with. Associated with Chronic Kidney Disease, Diabetes Mellitus, Thrombosis. Connected to 13 entities in the SciDEX knowledge graph.
No AI portrait yet
| Gene Symbol | P2Y12 |
| Function | P2Y12 on microglia mediates response to amyloid-beta[@moorhead2019]. The receptor is involved in microglial recruitment to plaques. Genetic variants may affect AD risk. |
| Molecular Weight | 39.4 kDa |
| Pathways | Pik3, PI3K pathway, purinergic signaling, synaptic plasticity, PI3K-AKT-mTOR signaling |
| GeneCards | P2Y12 |
| Human Protein Atlas | P2Y12 |
| Associated Diseases | ALS, Chronic Kidney Disease, diabetes, disease, epilepsy |
| Known Drugs/Compounds | P2Y12_inverse_agonists |
| Interactions | ALZHEIMER, AMYLOID, ATP, CD39, CD47, EPILEPSY |
| KG Connections | 90 knowledge graph edges |
| Databases | GeneCardsUniProtNCBI GeneHPASTRING |
Knowledge base pages for this entity
graph TD
P2Y12["P2Y12"]
Platelet_Aggregation["Platelet Aggregation"]
P2Y12 -->|"activates"| Platelet_Aggregation
Platelet["Platelet"]
P2Y12 -->|"expressed_in"| Platelet
Thrombosis{"Thrombosis"}
P2Y12 -->|"involved_in"| Thrombosis
ADCY["ADCY"]
P2Y12 -.->|"inhibits"| ADCY
cAMP["cAMP"]
P2Y12 -.->|"downregulates"| cAMP
Pik3["Pik3"]
P2Y12 -->|"activates"| Pik3
Adp["Adp"]
Adp -->|"activates"| P2Y12
Clopidogrel["Clopidogrel"]
Clopidogrel -->|"targets"| P2Y12
Ticagrelor["Ticagrelor"]
Ticagrelor -->|"targets"| P2Y12
style P2Y12 fill:#1a3a4a,stroke:#4fc3f7,stroke-width:3px,color:#4fc3f7| Target | Relation | Type | Str |
|---|---|---|---|
| PI3K pathway | activates | pathway | 0.80 |
| purinergic signaling | participates_in | pathway | 0.75 |
| microglia | expressed_in | cell_type | 0.75 |
| Alzheimer's disease | regulates | disease | 0.65 |
| autophagy pathway | participates_in | pathway | 0.60 |
| cardiovascular disease | regulates | disease | 0.60 |
| epilepsy | associated_with | disease | 0.60 |
| diabetes | associated_with | disease | 0.60 |
| neurodegeneration | biomarker_for | disease | 0.60 |
| neurodegeneration | interacts_with | disease | 0.60 |
| ALS | associated_with | disease | 0.60 |
| glymphatic clearance | participates_in | pathway | 0.60 |
| multiple sclerosis | activates | disease | 0.60 |
| Alzheimer's disease | activates | disease | 0.60 |
| neuroinflammation | activates | disease | 0.60 |
| blood-brain barrier | participates_in | pathway | 0.60 |
| neurodegeneration | regulates | disease | 0.55 |
| neurons | expressed_in | cell_type | 0.55 |
| tauopathy | expressed_in | disease | 0.55 |
| PSP | activates | gene | 0.55 |
| unfolded protein response | participates_in | pathway | 0.55 |
| DAM microglia | expressed_in | cell_type | 0.55 |
| tauopathy | activates | disease | 0.55 |
| oxidative stress response | participates_in | pathway | 0.55 |
| Alzheimer's disease | inhibits | disease | 0.55 |
| astrocytes | expressed_in | cell_type | 0.55 |
| neurodegeneration | activates | disease | 0.55 |
| PSP | inhibits | gene | 0.55 |
| TREM2 | activates | gene | 0.55 |
| tauopathy | regulates | disease | 0.55 |
| neuroinflammation | inhibits | disease | 0.55 |
| synaptic plasticity | participates_in | pathway | 0.55 |
| neuroinflammation | regulates | disease | 0.55 |
| PI3K | activates | gene | 0.55 |
| PI3K-AKT-mTOR signaling | participates_in | pathway | 0.55 |
| TMEM119 | activates | gene | 0.55 |
| disease | associated_with | disease | 0.50 |
| atherosclerosis | regulates | disease | 0.50 |
| Chronic Kidney Disease | associated_with | disease | 0.50 |
| DIABETES | associated_with | disease | 0.50 |
| DIABETES MELLITUS | associated_with | concept | 0.50 |
| disease | interacts_with | disease | 0.50 |
| HAPLN1 | associated_with | protein | 0.50 |
| GRM2 | associated_with | gene | 0.50 |
| GLUTAMATE | associated_with | concept | 0.50 |
| Neuron | interacts_with | cell_type | 0.50 |
| Cortex | inhibits | brain_region | 0.50 |
| Cortex | interacts_with | brain_region | 0.50 |
| Oligodendrocyte | inhibits | cell_type | 0.50 |
| BRAIN INJURY | regulates | concept | 0.50 |
| Source | Relation | Type | Str |
|---|---|---|---|
| P2Y12_inverse_agonists | inhibits | drug | 0.65 |
| ATP | associated_with | gene | 0.60 |
| P2RY12 | activates | gene | 0.55 |
| CD47 | activates | gene | 0.55 |
| GFAP | activates | gene | 0.55 |
| ATP | activates | gene | 0.55 |
| P2X7 | activates | gene | 0.55 |
| CD39 | activates | gene | 0.55 |
| P2X7 | inhibits | gene | 0.55 |
| microglia | inhibits | cell_type | 0.50 |
| EPILEPSY | interacts_with | gene | 0.50 |
| Autophagy | regulates | process | 0.50 |
| CCR5 | associated_with | gene | 0.50 |
| CDH23 | associated_with | gene | 0.50 |
| P2RY12 | associated_with | gene | 0.50 |
| P2RY12 | regulates | gene | 0.50 |
| P2Y12 RECEPTOR | regulates | protein | 0.50 |
| microglia | interacts_with | cell_type | 0.50 |
| P2Y12 RECEPTOR | interacts_with | protein | 0.50 |
| microglia | associated_with | cell_type | 0.50 |
| microglia | regulates | cell_type | 0.50 |
| P2Y12 RECEPTOR | expressed_in | protein | 0.50 |
| P2Y12 RECEPTOR | activates | protein | 0.50 |
| P2Y12 RECEPTOR | associated_with | protein | 0.50 |
| P2Y12 RECEPTOR | inhibits | protein | 0.50 |
| Neuroinflammation | activates | process | 0.50 |
| CX3CR1 | regulates | gene | 0.50 |
| AMYLOID | activates | gene | 0.50 |
| GENES | co_discussed | gene | 0.50 |
| NMDA | activates | protein | 0.50 |
| PI3K | activates | protein | 0.50 |
| ATP | co_expressed_with | protein | 0.50 |
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| Purinergic P2Y12 Inverse Agonist Therapy | 0.703 | neurodegeneration | Synaptic pruning by microglia in early A |
| Microglial P2Y12-Dependent Territorial Segregation of Synapt | 0.686 | synaptic biology | What determines the selectivity of compl |
| Female Microglia Exhibit Reduced P2Y12 Expression Conferring | 0.580 | neuroinflammation | How do regional, age, and sex-dependent |
| P2X7/P2Y12 Purinergic Signaling Connects Aβ Aggregation to S | 0.423 | neurodegeneration | How do perivascular cells specifically r |
Scientific analyses that reference this entity
neurodegeneration | 2026-04-17 | 7 hypotheses Top: 0.685
neurodegeneration | 2026-04-01 | 0 hypotheses
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| P2RY12 inhibition in atherosclerosis mouse model | validation | atherosclerosis | 0.900 | 0.00 | ApoE-deficient mice | proposed | N/A |
| VSMC cholesterol efflux and P2RY12 signaling | exploratory | atherosclerosis | 0.900 | 0.00 | cultured VSMCs | proposed | N/A |
| Leukocyte gene expression analysis in COVID-19 patients | exploratory | COVID-19 | 0.900 | 0.00 | human leukocytes from COVID-19 | proposed | N/A |
| P2RY12 regulation of autophagy in VSMCs | exploratory | atherosclerosis | 0.900 | 0.00 | cultured VSMCs | proposed | N/A |
| P2RY12-MTOR pathway interaction in VSMCs | exploratory | atherosclerosis | 0.850 | 0.00 | cultured VSMCs | proposed | N/A |
| In vivo autophagy modulation in atherosclerotic mice | validation | atherosclerosis | 0.850 | 0.00 | ApoE-deficient mice | proposed | N/A |
| s:** - GPR32 knockout in microglia should worsen neuroinflammation if | falsification | Neuroinflammation | 0.400 | 0.50 | cell_line | proposed | $80,000 |
| Proposed experiment from debate on Synaptic pruning by microglia in ea | falsification | Neuroinflammation | 0.400 | 0.50 | mouse | proposed | $240,000 |
| FTD Microglia Role: Protective vs Destructive Mechanism Study | validation | Neuroinflammation | 0.400 | 0.50 | human | proposed | $2,960,000 |
| Purinergic Signaling Dysfunction Validation in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Beyond Activation: Characterizing Microglial Functional Phenotypes. [PMID:34571885] | Lier J, Streit WJ, Bechmann I | Cells | 2021 | 2 |
| The P2RY12 receptor promotes VSMC-derived foam cell formation by inhibiting auto [PMID:32160082] | Pi S, Mao L, Chen J, Shi H, Liu Y, Guo X | Autophagy | 2021 | 2 |
| Role of P2Y(12) Receptor in Thrombosis. [PMID:27628007] | Zhang Y, Zhang S, Ding Z | Adv Exp Med Biol | 2017 | 1 |
| P2 purinergic receptors in systemic lupus erythematosus: from experimental findi [PMID:41825304] | Renaudineau Y, Brooks W | Current opinion in immunology | 2026 | 0 |
| The Dual Role of P2RY12: Impact of Polymorphism and Expression on Ischemic Event [PMID:41903930] | Li J, Gong Z, Wang S, Gu J, Wu S, Pang J | Journal of thrombosis and haem | 2026 | 0 |
| Association of P2Y12 Polymorphisms With the Risk of Ischemic Stroke Subtypes. [PMID:41761998] | Wu C, Chen Y, Chen J, Wei X, Zhang Z | Revista de neurologia | 2026 | 0 |
| [Advantageous therapeutic pathways and mechanisms of Jianpi Huogu Formula in tre [PMID:41814722] | Li T, Zhang C, Jia Y, Chen WH, Lin N, Zh | Zhongguo Zhong yao za zhi = Zh | 2026 | 0 |
| Clopidogrel Administration Impairs Neurovascular Unit Recovery and Exacerbates A [PMID:41898413] | Paul M, Paul JW, Hinwood M, Hood RJ, Mar | International journal of molec | 2026 | 0 |
| Pan-cancer T cell atlas links a cellular stress response state to immunotherapy [PMID:37248301] | ["Chu Y", "Dai E", "Li Y", "Han G", "Pei | Nature medicine | 2023 | 0 |
| Updates on systemic consequences of coeliac disease. [PMID:33199835] | Katri Kaukinen | Nature reviews. Gastroenterolo | 2021 | 0 |
| Immune-related adverse events predict responses to PD-1 blockade immunotherapy i [PMID:33890283] | ["Lu L", "Xing K", "Wei W", "Ling Y", "L | International journal of cance | 2021 | 0 |
| Endogenous TLR2 ligand embedded in the catalytic region of human cysteinyl-tRNA [PMID:32461342] | ["Cho S", "Kim S", "Lee Y", "Song E", "K | Journal for immunotherapy of c | 2020 | 0 |
| Assemblies of Perisomatic GABAergic Neurons in the Developing Barrel Cortex. [PMID:31780328] | ["Modol L", "Bollmann Y", "Tressard T", | Neuron | 2020 | 0 |
| Blood from heparin tubes is an acceptable alternative to assess hematocrit deter [PMID:30903756] | Pekar Jean-David; Carpentier Thomas; Mab | Clinical chemistry and laborat | 2019 | 0 |
| A Unique Microglia Type Associated with Restricting Development of Alzheimer's D [PMID:28602351] | ["Keren-Shaul H", "Spinrad A", "Weiner A | Cell | 2017 | 0 |
| An Unusual Presentation of Acute Appendicitis With Mobile Cecum Syndrome [PMID:25943697] | Jia-Yuh Jean; Hsu-Hung Tseng; Wen-Shih K | Pediatrics and neonatology | 2015 | 0 |
| Platelet P2Y12 receptor inhibition by thienopyridines: status and future. [PMID:19678800] | ["Porto I", "Giubilato S", "De Maria G", | Expert opinion on investigatio | 2009 | 0 |
| Pten regulates neuronal arborization and social interaction in mice. [PMID:16675393] | ["Kwon C", "Luikart B", "Powell C", "Zho | Neuron | 2006 | 0 |
| Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2 [PMID:15967851] | ["Wiviott S", "Antman E", "Winters K", " | Circulation | 2005 | 0 |
Multi-agent debates referencing this entity
closed · Rounds: 4 · Score: 0.50 · 2026-04-18
closed · Rounds: 4 · Score: 0.95 · 2026-04-01
Hypotheses and analyses mentioning P2Y12 in their description or question text
No additional research found